Now showing items 21-40 of 2905

    • Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study. 

      Dillon, MT; Grove, L; Newbold, KL; Shaw, H; Brown, NF; Mendell, J; Chen, S; Beckman, RA; Jennings, A; Ricamara, M; Greenberg, J; Forster, M; Harrington, KJ (2018-10-16)
      Purpose: Patritumab plus cetuximab with platinum as first-line therapy for patients with recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) was evaluated for safety and to determine the ...
    • A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). 

      Turner, NC; Telli, ML; Rugo, HS; Mailliez, A; Ettl, J; Grischke, E-M; Mina, LA; Balmaña, J; Fasching, PA; Hurvitz, SA; Wardley, AM; Chappey, C; Hannah, AL; Robson, ME (2018-12-18)
      PURPOSE: To assess talazoparib activity in germline BRCA1/2 mutation carriers with advanced breast cancer (aBC). EXPERIMENTAL DESIGN: ABRAZO (NCT02034916) was a two-cohort, two-stage, phase II study of talazoparib (1 mg/day) ...
    • Publisher Correction: Cancer genetics, precision prevention and a call to action. 

      Turnbull, C; Sud, A; Houlston, RS (2019-01)
      In the version of this article originally published, there was an error in the second-to-last sentence of the abstract. In this sentence, the final phrase "to identify carriers of first-wave gene mutation carriers" should ...
    • Evaluation of a Dual Isolation Width Acquisition (DIWA) method for isobaric labelling ratio decompression. 

      Roumeliotis, TI; Weisser, H; Choudhary, J (2018-12-21)
      Isobaric labelling is a highly precise approach for protein quantification. However, due to the isolation interference problem, isobaric tagging suffers from ratio underestimation at the MS2 level. The use of narrow isolation ...
    • Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. 

      Went, M; Sud, A; Speedy, H; Sunter, NJ; Försti, A; Law, PJ; Johnson, DC; Mirabella, F; Holroyd, A; Li, N; Orlando, G; Weinhold, N; van Duin, M; Chen, B; Mitchell, JS; Mansouri, L; Juliusson, G; Smedby, KE; Jayne, S; Majid, A; Dearden, C; Allsup, DJ; Bailey, JR; Pratt, G; Pepper, C; Fegan, C; Rosenquist, R; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Einsele, H; Gregory, WM; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Nickel, J; Nöthen, MM; da Silva Filho, MI; Thomsen, H; Walker, BA; Broyl, A; Davies, FE; Hansson, M; Goldschmidt, H; Dyer, MJS; Kaiser, M; Sonneveld, P; Morgan, GJ; Hemminki, K; Nilsson, B; Catovsky, D; Allan, JM; Houlston, RS (2018-12-21)
      The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma ...
    • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. 

      Mavaddat, N; Michailidou, K; Dennis, J; Lush, M; Fachal, L; Lee, A; Tyrer, JP; Chen, T-H; Wang, Q; Bolla, MK; Yang, X; Adank, MA; Ahearn, T; Aittomäki, K; Allen, J; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arndt, V; Aronson, KJ; Auer, PL; Auvinen, P; Barrdahl, M; Beane Freeman, LE; Beckmann, MW; Behrens, S; Benitez, J; Bermisheva, M; Bernstein, L; Blomqvist, C; Bogdanova, NV; Bojesen, SE; Bonanni, B; Børresen-Dale, A-L; Brauch, H; Bremer, M; Brenner, H; Brentnall, A; Brock, IW; Brooks-Wilson, A; Brucker, SY; Brüning, T; Burwinkel, B; Campa, D; Carter, BD; Castelao, JE; Chanock, SJ; Chlebowski, R; Christiansen, H; Clarke, CL; Collée, JM; Cordina-Duverger, E; Cornelissen, S; Couch, FJ; Cox, A; Cross, SS; Czene, K; Daly, MB; Devilee, P; Dörk, T; Dos-Santos-Silva, I; Dumont, M; Durcan, L; Dwek, M; Eccles, DM; Ekici, AB; Eliassen, AH; Ellberg, C; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Figueroa, J; Fletcher, O; Flyger, H; Försti, A; Fritschi, L; Gabrielson, M; Gago-Dominguez, M; Gapstur, SM; García-Sáenz, JA; Gaudet, MM; Georgoulias, V; Giles, GG; Gilyazova, IR; Glendon, G; Goldberg, MS; Goldgar, DE; González-Neira, A; Grenaker Alnæs, GI; Grip, M; Gronwald, J; Grundy, A; Guénel, P; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hamann, U; Hankinson, SE; Harkness, EF; Hart, SN; He, W; Hein, A; Heyworth, J; Hillemanns, P; Hollestelle, A; Hooning, MJ; Hoover, RN; Hopper, JL; Howell, A; Huang, G; Humphreys, K; Hunter, DJ; Jakimovska, M; Jakubowska, A; Janni, W; John, EM; Johnson, N; Jones, ME; Jukkola-Vuorinen, A; Jung, A; Kaaks, R; Kaczmarek, K; Kataja, V; Keeman, R; Kerin, MJ; Khusnutdinova, E; Kiiski, JI; Knight, JA; Ko, Y-D; Kosma, V-M; Koutros, S; Kristensen, VN; Krüger, U; Kühl, T; Lambrechts, D; Le Marchand, L; Lee, E; Lejbkowicz, F; Lilyquist, J; Lindblom, A; Lindström, S; Lissowska, J; Lo, W-Y; Loibl, S; Long, J; Lubiński, J; Lux, MP; MacInnis, RJ; Maishman, T; Makalic, E; Maleva Kostovska, I; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Martinez, ME; Mavroudis, D; McLean, C; Meindl, A; Menon, U; Middha, P; Miller, N; Moreno, F; Mulligan, AM; Mulot, C; Muñoz-Garzon, VM; Neuhausen, SL; Nevanlinna, H; Neven, P; Newman, WG; Nielsen, SF; Nordestgaard, BG; Norman, A; Offit, K; Olson, JE; Olsson, H; Orr, N; Pankratz, VS; Park-Simon, T-W; Perez, JIA; Pérez-Barrios, C; Peterlongo, P; Peto, J; Pinchev, M; Plaseska-Karanfilska, D; Polley, EC; Prentice, R; Presneau, N; Prokofyeva, D; Purrington, K; Pylkäs, K; Rack, B; Radice, P; Rau-Murthy, R; Rennert, G; Rennert, HS; Rhenius, V; Robson, M; Romero, A; Ruddy, KJ; Ruebner, M; Saloustros, E; Sandler, DP; Sawyer, EJ; Schmidt, DF; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schumacher, F; Schürmann, P; Schwentner, L; Scott, C; Scott, RJ; Seynaeve, C; Shah, M; Sherman, ME; Shrubsole, MJ; Shu, X-O; Slager, S; Smeets, A; Sohn, C; Soucy, P; Southey, MC; Spinelli, JJ; Stegmaier, C; Stone, J; Swerdlow, AJ; Tamimi, RM; Tapper, WJ; Taylor, JA; Terry, MB; Thöne, K; Tollenaar, RAEM; Tomlinson, I; Truong, T; Tzardi, M; Ulmer, H-U; Untch, M; Vachon, CM; van Veen, EM; Vijai, J; Weinberg, CR; Wendt, C; Whittemore, AS; Wildiers, H; Willett, W; Winqvist, R; Wolk, A; Yang, XR; Yannoukakos, D; Zhang, Y; Zheng, W; Ziogas, A; ABCTB Investigators; kConFab/AOCS Investigators; NBCS Collaborators; Dunning, AM; Thompson, DJ; Chenevix-Trench, G; Chang-Claude, J; Schmidt, MK; Hall, P; Milne, RL; Pharoah, PDP; Antoniou, AC; Chatterjee, N; Kraft, P; García-Closas, M; Simard, J; Easton, DF (2019-01-03)
      Stratification of women according to their risk of breast cancer based on polygenic risk scores (PRSs) could improve screening and prevention strategies. Our aim was to develop PRSs, optimized for prediction of estrogen ...
    • INTEND II randomized clinical trial of intraoperative duct endoscopy in pathological nipple discharge. 

      Gui, G; Agusti, A; Twelves, D; Tang, S; Kabir, M; Montgomery, C; Nerurkar, A; Osin, P; Isacke, C (2018-11)
      BACKGROUND: The majority of lesions resulting in pathological nipple discharge are benign. Conventional surgery is undirected and targeting the causative lesion by duct endoscopy may enable more accurate surgery with fewer ...
    • Beam selection for stereotactic ablative radiotherapy using Cyberknife with multileaf collimation. 

      Bedford, JL; Ziegenhein, P; Nill, S; Oelfke, U (2018-12-19)
      The Cyberknife system (Accuray Inc., Sunnyvale, CA) enables radiotherapy using stereotactic ablative body radiotherapy (SABR) with a large number of non-coplanar beam orientations. Recently, a multileaf collimator has also ...
    • Dose prescription with spatial uncertainty for peripheral lung SBRT. 

      Bedford, JL; Blasiak-Wal, I; Hansen, VN (2018-12-14)
      Current clinical practice is to prescribe to 95% of the planning target volume (PTV) in 4D stereotactic body radiotherapy (SBRT) for lung. Frequently the PTV margin has a very low physical density so that the internal ...
    • Homeobox B13 G84E Mutation and Prostate Cancer Risk. 

      Nyberg, T; Govindasami, K; Leslie, G; Dadaev, T; Bancroft, E; Ni Raghallaigh, H; Brook, MN; Hussain, N; Keating, D; Lee, A; McMahon, R; Morgan, A; Mullen, A; Osborne, A; Rageevakumar, R; UK Genetic Prostate Cancer Study Collaborators; Kote-Jarai, Z; Eeles, R; Antoniou, AC (2018-12-07)
      BACKGROUND: The homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutation is uncertain. OBJECTIVE: To obtain ...
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. 

      Nichols, HB; Schoemaker, MJ; Cai, J; Xu, J; Wright, LB; Brook, MN; Jones, ME; Adami, H-O; Baglietto, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kitahara, CM; Larsson, SC; Linet, M; Merritt, MA; Milne, RL; Pala, V; Palmer, JR; Peeters, PH; Riboli, E; Sund, M; Tamimi, RM; Tjønneland, A; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Wolk, A; Zheng, W; Weinberg, CR; Swerdlow, AJ; Sandler, DP (2018-12-11)
      Background: Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or ...
    • Calculation of absorbed dose in radiotherapy by solution of the linear Boltzmann transport equations. 

      Bedford, JL (2018-11-14)
      Over the last decade, dose calculations which solve the linear Boltzmann transport equations have been introduced into clinical practice and are now in widespread use. However, knowledge in the radiotherapy community ...
    • Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL). 

      Dearnaley, D; Griffin, CL; Lewis, R; Mayles, P; Mayles, H; Naismith, OF; Harris, V; Scrase, CD; Staffurth, J; Syndikus, I; Zarkar, A; Ford, DR; Rimmer, YL; Horan, G; Khoo, V; Frew, J; Venkitaraman, R; Hall, E (2018-12-06)
      PURPOSE: To establish the toxicity profile of high-dose pelvic lymph node intensity-modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at multiple centers. METHODS AND MATERIALS: In this phase ...
    • Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. 

      Moreno, L; Casanova, M; Chisholm, JC; Berlanga, P; Chastagner, PB; Baruchel, S; Amoroso, L; Gallego Melcón, S; Gerber, NU; Bisogno, G; Fagioli, F; Geoerger, B; Glade Bender, JL; Aerts, I; Bergeron, C; Hingorani, P; Elias, I; Simcock, M; Ferrara, S; Le Bruchec, Y; Slepetis, R; Chen, N; Vassal, G (2018-09)
      BACKGROUND: nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with ...
    • The National Cancer Institute Cohort Consortium: An International Pooling Collaboration of 58 Cohorts from 20 Countries. 

      Swerdlow, AJ; Harvey, CE; Milne, RL; Pottinger, CA; Vachon, CM; Wilkens, LR; Gapstur, SM; Johansson, M; Weiderpass, E; Winn, DM (2018-11)
      Cohort studies have been central to the establishment of the known causes of cancer. To dissect cancer etiology in more detail-for instance, for personalized risk prediction and prevention, assessment of risks of subtypes ...
    • RIPK1 and Caspase-8 Ensure Chromosome Stability Independently of Their Role in Cell Death and Inflammation. 

      Liccardi, G; Ramos Garcia, L; Tenev, T; Annibaldi, A; Legrand, AJ; Robertson, D; Feltham, R; Anderton, H; Darding, M; Peltzer, N; Dannappel, M; Schünke, H; Fava, LL; Haschka, MD; Glatter, T; Nesvizhskii, A; Schmidt, A; Harris, PA; Bertin, J; Gough, PJ; Villunger, A; Silke, J; Pasparakis, M; Bianchi, K; Meier, P (2018-12-28)
      Receptor-interacting protein kinase (RIPK) 1 functions as a key mediator of tissue homeostasis via formation of Caspase-8 activating ripoptosome complexes, positively and negatively regulating apoptosis, necroptosis, and ...
    • Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. 

      Johnston, S; Puhalla, S; Wheatley, D; Ring, A; Barry, P; Holcombe, C; Boileau, JF; Provencher, L; Robidoux, A; Rimawi, M; McIntosh, SA; Shalaby, I; Stein, RC; Thirlwell, M; Dolling, D; Morden, J; Snowdon, C; Perry, S; Cornman, C; Batten, LM; Jeffs, LK; Dodson, A; Martins, V; Modi, A; Osborne, CK; Pogue-Geile, KL; Cheang, MCU; Wolmark, N; Julian, TB; Fisher, K; MacKenzie, M; Wilcox, M; Huang Bartlett, C; Koehler, M; Dowsett, M; Bliss, JM; Jacobs, SA (2018-12-06)
      PURPOSE: CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase II randomized trial that evaluated the effects of combination ...
    • The impact of 2D cine MR imaging parameters on automated tumor and organ localization for MR-guided real-time adaptive radiotherapy. 

      Menten, MJ; Fast, MF; Wetscherek, A; Rank, CM; Kachelrieß, M; Collins, DJ; Nill, S; Oelfke, U (2018-11-22)
      2D cine MR imaging may be utilized to monitor rapidly moving tumors and organs-at-risk for real-time adaptive radiotherapy. This study systematically investigates the impact of geometric imaging parameters on the ability ...
    • A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors 

      Menon, M; Elliott, RJ; Bowers, L; Balan, N; Rafiq, R; Costa-Cabral, S; Munkonge, F; Trinidade, I; Ashworth, A; Lord, C
    • Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts 

      Calvo, F; Ferrari, N; Ranftl, R; Chicherova, I; Slaven, ND; Moeendarbary, E; Farrugia, AJ; Lam, M; Semiannikova, M; Westergaard, MCW; Tchou, J; Magnani, L
      Aggressive behaviours of solid tumours are influenced by the tumour microenvironment. Multiple signalling pathways can influence the behaviour of stromal fibroblasts in tumours, but how these events are coordinated to ...